AccScience Publishing / MI / Online First / DOI: 10.36922/mi.3757
Submit to MI
Cite this article
3
Download
117
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW

Comparison of immune response parameters between homologous and heterologous COVID-19 vaccines: A scoping review

Samantha Si Mei Khoo1 ,  Kang Wei Tan1 ,  Ashwini Mahendran1 ,  Saatheeyavaane Bhuvanendran1 ,  Ammu Kutty Radhakrishnan1*
Show Less
1 Food As Medicine Research Strength, Jeffery Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Selangor, Malaysia
MI, 3757 https://doi.org/10.36922/mi.3757
Submitted: 24 May 2024 | Accepted: 24 June 2024 | Published: 16 October 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

It has been over 4 years since the emergence of the coronavirus disease 2019 (COVID-19) pandemic. This highly contagious respiratory infection has endangered the health of millions and significantly impacted healthcare systems and economies. Vaccines are believed to confer immunity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19, reducing both the severity of infection and the spread of the virus. Within a short period, various COVID-19 vaccines were developed and extensively tested before being approved by the WHO for distribution and administration. Now, due to concerns about emerging new strains of the virus and limited vaccine availability, a heterologous vaccine strategy is being deployed. Therefore, this paper aims to conduct a scoping review of existing evidence to compare the immunogenicity of heterologous vaccines with homologous vaccines and determine which confers better immunity against COVID-19. A literature search was conducted across three electronic databases (Ovid MEDLINE, PubMed, and Scopus). The retrieved studies were screened for relevance and eligibility using the online platform Covidence. A total of 31 articles were shortlisted for data extraction and analysis. Among these, 21 were observational studies, and 10 were clinical trials. The analysis demonstrated that participants who received heterologous vaccination regimens generated higher levels of IgG antibodies against the spike protein of SARS-CoV-2, antibodies targeting the receptor-binding domain, and T-cell responses compared to those who received homologous vaccination regimens. Furthermore, heterologous vaccination produced higher titers of neutralizing antibodies against several variants of concern (VOC), including Alpha, Beta, Gamma, Delta, and Omicron. No severe vaccine-related adverse events were reported in these studies, and common local and systemic side effects were manageable. Overall, heterologous vaccination regimes induced strong humoral and cellular immunity, comparable to homologous vaccination regimes, with stronger neutralizing antibody activity against VOCs.

Keywords
COVID-19
SARS-CoV-2
Heterologous vaccines
Homologous vaccines
Immunogenicity
Funding
None.
Conflict of interest
The authors declare that they have no competing interests.
References
  1. WHO. COVID-19 Dashboard. World Health Organization; 2022. Available from: https://covid19.who.int [Last accessed on 2022 Feb 25].

 

  1. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024.

 

  1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141-154. doi: 10.1038/s41579-020-00459-7

 

  1. WHO. COVID-19 Vaccines. World Health Organization; 2022. Available from: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/covid-19-vaccines [Last accessed on 2022 Feb 25].

 

  1. WHO. Interim Recommendations for Heterologous COVID-19 Vaccine Schedules 2021. World Health Organization; 2021. Available from: https://www.who.int/publications/i/ item/who-2019-ncov-vaccines-sage-recommendation-heterologous-schedules [Last accessed on 2022 Feb 25].

 

  1. Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022;11:337-343. doi: 10.1080/22221751.2021.2022440

 

  1. Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022;386:1046-1057. doi: 10.1056/NEJMoa2116414

 

  1. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/ BNT162b2 vaccination. Nat Med. 2021;27:1525-1529. doi: 10.1038/s41591-021-01449-9

 

  1. Behrens GM, Cossmann A, Stankov MV, et al. SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/ BNT162b2 vaccination. Lancet. 2021;398:1041-1042. doi: 10.1016/S0140-6736(21)01891-2

 

  1. Benning L, Tollner M, Hidmark A, et al. Heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers. Vaccines (Basel). 2021;9:857. doi: 10.3390/vaccines9080857

 

  1. Borobia AM, Carcas AJ, Perez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121-130. doi: 10.1016/S0140-6736(21)01420-3

 

  1. Clemens SAC, Folegatti PM, Emary KRW, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nat Commun. 2021;12:5861. doi: 10.1038/s41467-021-25982-w

 

  1. Firinu D, Perra A, Campagna M, et al. Evaluation of antibody response to heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2: An observational study. Vaccines (Basel). 2021;9:1478. doi: 10.3390/vaccines9121478

 

  1. Glockner S, Hornung F, Baier M, et al. Robust neutralizing antibody levels detected after either SARS-CoV-2 vaccination or one year after infection. Viruses. 2021;13:2003. doi: 10.3390/v13102003

 

  1. Gram MA, Nielsen J, Schelde AB, et al. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. PLoS Med. 2021;18:e1003874. doi: 10.1371/journal.pmed.1003874

 

  1. Gross R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine. 2022;75:103761. doi: 10.1016/j.ebiom.2021.103761

 

  1. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study. Lancet Respir Med. 2021;9:1255-1265. doi: 10.1016/S2213-2600(21)00357-X

 

  1. Kant R, Dwivedi G, Zaman K, et al. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin. J Travel Med. 2021;28:taab166. doi: 10.1093/jtm/taab166

 

  1. Khong KW, Liu D, Leung KY, et al. Antibody response of combination of BNT162b2 and coronavac platforms of COVID-19 vaccines against Omicron variant. Vaccines (Basel). 2022;10:160. doi: 10.3390/vaccines10020160

 

  1. Khoo NKH, Lim JME, Gill US, et al. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med. 2022;3:104-118.e4. doi: 10.1016/j.medj.2021.12.004

 

  1. Li J, Hou L, Guo X, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: A randomized phase 4 trial. Nat Med. 2022;28:401-419. doi: 10.1038/s41591-021-01677-z

 

  1. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial. Lancet. 2021;398:856-869. doi: 10.1016/S0140-6736(21)01694-9

 

  1. Moghnieh R, Mekdashi R, El-Hassan S, et al. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon. Vaccine. 2021;39:6713-6719. doi: 10.1016/j.vaccine.2021.10.007

 

  1. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258-2276. doi: 10.1016/S0140-6736(21)02717-3

 

  1. Normark J, Vikstrom L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. N Engl J Med. 2021;385:1049-1051. doi: 10.1056/NEJMc2110716

 

  1. Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A. Humoral immune response after different SARS-CoV-2 vaccination regimens. BMC Med. 2022;20:31. doi: 10.1186/s12916-021-02231-x

 

  1. Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021;27:1530-1535. doi: 10.1038/s41591-021-01464-w

 

  1. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): A single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2022;399:36-49. doi: 10.1016/S0140-6736(21)02718-5

 

  1. Tenbusch M, Schumacher S, Vogel E, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021;21:1212-1213. doi: 10.1016/S1473-3099(21)00420-5

 

  1. Vallée A, Vasse M, Mazaux L, et al. An immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with ChAdOx1-S and BNT162b2 vaccines. J Clin Med. 2021;10:3817. doi: 10.3390/jcm10173817

 

  1. Zhang R, Liu D, Leung KY, et al. Immunogenicity of a heterologous prime-boost COVID-19 vaccination with mRNA and inactivated virus vaccines compared with homologous vaccination strategy against SARS-CoV-2 variants. Vaccines (Basel). 2022;10:72. doi: 10.3390/vaccines10010072

 

  1. Sila T, Suriyaamorn W, Toh C, et al. Factors associated with the worsening of COVID-19 symptoms among cohorts in community-or home-isolation care in southern Thailand. Front Public Health. 2024;12:1350304. doi: 10.3389/fpubh.2024.1350304

 

  1. Xu H, Li H, You H, et al. Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: Real-world study in Jilin Province, China. Emerg Microbes Infect. 2023;12:2149935. doi: 10.1080/22221751.2022.2149935

 

  1. Mok CKP, Chen C, Yiu K, et al. A randomized clinical trial using CoronaVac or BNT162b2 vaccine as a third dose in adults vaccinated with two doses of CoronaVac. Am J Respir Crit Care Med. 2022;205:844-847. doi: 10.1164/rccm.202111-2655LE

 

  1. Gerhards C, Thiaucourt M, Hetjens M, Haselmann V, Neumaier M, Kittel M. Heterologous Vector-mRNA Based SARS-CoV-2 vaccination strategy appears superior to a homologous vector-based vaccination scheme in german healthcare workers regarding humoral SARS-CoV-2 response indicating a high boosting effect by mRNA vaccines. Vaccines (Basel). 2023;11:701. doi: 10.3390/vaccines11030701

 

  1. Intapiboon P, Seepathomnarong P, Ongarj J, et al. Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population. Vaccines (Basel). 2021;9:1375. doi: 10.3390/vaccines9121375

 

  1. Spencer AJ, McKay PF, Belij-Rammerstorfer S, et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat Commun. 2021;12:2893. doi: 10.1038/s41467-021-23173-1

 

  1. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20:615-632. doi: 10.1038/s41577-020-00434-6

 

  1. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21:475-484. doi: 10.1038/s41577-021-00578-z

 

  1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205-1211. doi: 10.1038/s41591-021-01377-8
Share
Back to top
Microbes & Immunity, Electronic ISSN: 3029-2883 Print ISSN: 3041-0886, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept